Cyclophosphamide (CPA) is widely used for peripheral blood stem cell mobilization, and a dose adjustment of CPA in the presence of renal failure has not been suggested. However, we describe a myeloma patient with renal failure (serum creatinine 4.2 mg/dl, creatinine clearance 11.2 ml/min) receiving CPA 2 g/m 2 for 2 days, who developed unexpectedly severe toxicity, including myopericarditis and prolonged myelosuppression. The serial serum concentrations of CPA metabolites were persistently much higher than those in a myeloma patient with normal renal function. We consider, therefore, that the dose of CPA should be reduced in the presence of severe renal failure when used as high-dose therapy or to mobilize peripheral blood stem cells. Bone Marrow Transplantation (2000) 26, 685-688. Keywords: cyclophosphamide; cardiotoxicity; pericardial effusion; renal failure; myeloma Multiple myeloma is a neoplastic disorder of plasma cells which is considered to be incurable with standard chemotherapy.
Multiple myeloma is a neoplastic disorder of plasma cells which is considered to be incurable with standard chemotherapy.
1 High-dose chemotherapy followed by hematopoietic stem cell support has resulted in prolonged event-free and overall survival. 2 However, eligibility criteria for highdose chemotherapy protocols generally require patients to have normal vital organ function. Impairment of renal function is one of frequent complications of multiple myeloma and affects the pharmacokinetics of variety of drugs.
Cyclophosphamide (CPA) is one of the most useful antineoplastic agents also widely used for peripheral blood stem cell mobilization. However, little information is available about the pharmacokinetics of CPA in renal insufficiency. Bramwell et al reported that the alkylating activity of CPA is influenced more by the wide individual variation in CPA breakdown than by decreased renal function 3, 4 Grochow et al 5 failed to show any correlation between the severity of renal insufficiency and hematopoietic toxicity. Therefore, adjusting CPA doses in the presence of renal insufficiency has not been recommended. 5, 6 However, we experienced a myeloma patient with renal failure, who received 4 g/m 2 of CPA for peripheral blood stem cell (PBSC) mobilization and eventually developed severe myopericarditis and prolonged myelosuppression. We present the clinical course and discuss the pharmacokinetics of CPA in renal failure.
Case report
A 36-year-old woman with persistent fever was discovered to have Bence-Jones proteinuria, anemia and renal failure with a serum creatinine of 3.1 mg/dl, that rose to 6.5 mg/dl over 2 months. A skeletal survey demonstrated advanced osteolytic lesions. Bone marrow aspiration showed an increase in atypical plasma cells, thus establishing a diagnosis of multiple myeloma, stage IIIB, according to the criteria by Durie and Salmon. Two courses of VAD therapy (vincristine 0.4 mg/body for 4 days, doxorubicin 9 mg/m 2 for 4 days, dexamethazone 40 mg/body for days 1-4, 9-12 and 17-20) resulted in partial response and a decrease in serum creatinine level (from 6.5 mg/dl to 2.9 mg/dl). 7 Because of her young age and the fever, which spoilt her quality of life, she was referred to our hospital for evaluating for autologous hematopoietic stem cell transplantation. We considered that she was eligible for high-dose therapy, because the renal function had improved after the initial chemotherapy. After obtaining informed consent concerning the risk of chemotherapy-related toxicities potentially being enhanced by the renal insufficiency, CPA was given intravenously over 1 h at a dose of 2 g/m 2 for 2 consecutive days to mobilize PBSCs, followed by subcutaneous granulocyte colony-stimulating factor administration (5 g/kg twice daily). We split the dose of cyclophosphamide into 2-day infusions, because in animals fractionated cyclophosphamide was less toxic than was a single infusion of the same total dose and therapeutically more effective, although there have been no human data. 8 The hydration protocol was 2000 ml/day on day 0, 3000 ml/day on days 1 and 2, and 2000 ml/day on days 3 to 7. Blood samples were taken before, and 1, 2, 3, 4, 5, 6, 9, 12, 24, 48 h after the initiation of the CPA infusion and the serum concentration of CPA and its metabolites were determined ( Figure  1 ). From day 3 after CPA therapy, she developed tumorlysis syndrome manifested by high-grade fever, elevation of serum uric acid and potassium levels. This improved with dexamethazone 8 mg/day for 2 days. On day 10, she complained of severe chest pain, aggravated by breathing, and a sinus tachycardia (heart rates 150-160 beats/min) despite low-grade fever. Chest X-ray revealed bilateral pleural effusions and an increase in cardiothoracic ratio. Echocardiography showed a pericardial effusion of approximately 100-150 ml without signs of tamponade. Electrocardiography (ECG) showed low voltage in the limb leads without significant ST-T change. Thus, myopericarditis probably due to CPA toxicity was diagnosed. The pericardial effusion increased gradually and pulmonary edema appeared on day 15 ( Figure 2 ). Pericardiocentesis was performed and 650 ml of exudate fluid were drained. Examination of the fluid showed no microorganisms and no myeloma cell infiltration. After pericardiocentesis, her condition improved dramatically. The days to reach neutrophils 500/l and 1000/l were 20 and 21 days, respectively. The last transfusion of platelet-rich plasma was on day 22. From day 22, PBSC apheresis was performed on 3 consecutive days and we obtained 1.98 × 10 6 cells/kg CD34-positive cells. The clinical findings including ECG, echocardiography, and chest X-ray returned to almost normal levels thereafter. However, the decrease in Bence-Jones proteinuria was transient and renal function was not improved by CPA therapy. Therefore, we have withheld high-dose therapy to date.
Serum concentration of cyclophosphamide
Serum concentrations of CPA and its metabolites were determined by thin layer chromatography. 9 By this method, total alkylating activity, not of specific metabolites, was measured. Figure 1 shows the serial serum concentrations for CPA and its active metabolites in the present patient (CG) and those in two myeloma patients with normal renal function (RM and KT). The decline in the concentrations of CPA and its metabolites in RM and KT was comparable to the data described previously (terminal half-life of 7.47 ± 3.95 h and 21.6 ± 10.1 h, respectively). 3 In contrast, the decline in serum CPA level was slow in CG. Moreover, the serum concentration of CPA metabolites continued to elevate during the first 24 h. Uses of other drugs that might increase CPA metabolites, such as allopurinol or cimetidine, did not differ in the three patients. 6, 10 Neither CPA nor its metabolites were detected in the pericardial fluid.
Discussion
We considered that this patient was suitable for peripheral blood stem cell transplantation, because several investigators have performed such treatments in myeloma patients with renal failure. 11, 12 We employed the combination of CPA and G-CSF to mobilize PBSC, because she had VADresistant disease and high-dose CPA has been shown to be effective in refractory myeloma. 13 However, she developed severe myopericarditis after high-dose CPA. Myocarditis caused by a viral infection should be considered in the differential diagnosis. However, antibody titers for viruses that might cause myocarditis did not change during this period. Although the antibody titers may not have risen because of the immunodeficiency caused by the myeloma, it is very likely that the myopericarditis was caused by cyclophosphamide toxicity, because the clinical course was typical for cyclophosphamide cardiotoxicity and the alkylating activity was far higher than that seen in patients with normal renal function.
Cardiotoxicity associated with high-dose CPA therapy was first reported in 1971.
14 Subsequently, Gottdiener et al 15 investigated the cardiac effects of CPA in 32 patients who received 180 mg/kg over 4 days. Pericardial effusions occurred in 33% of the patients and congestive heart failure in 28% within 3 weeks after the initiation of therapy. Six of these patients (19%) died of myocardial failure. Pathologic findings included endothelial injury and hemorrhagic myopericarditis. In a retrospective study of bone marrow transplant patients, CPA cardiotoxicity has been shown to correlate better with dose per body-surface area than dose per body weight. 16 The pharmacology of CPA metabolites has been extensively studied. 5 The parent drug has no alkylating activity and the liver has been demonstrated to be the principal site of CPA activation. Four of the metabolites of CPA exhibit cytotoxic properties in vitro; 4-hydroxycyclophosphamide, phosphoramide mustard, nornitrogen mustard, and acrolein. These metabolites are eliminated by the kidneys, whereas elimination of CPA is predominantly by metabolism to both active and inactive compounds. 5 These facts support the idea of decreasing the dose of CPA in renal insufficiency. However, Bramwell et al found such wide individual variations in cyclophosphamide break-down that they could not establish a correlation between cyclophosphamide or alkylating metabolites and renal insufficiency.
3,4 They also showed that further metabolism before renal elimination was an important route of removal of alkylating activity. Grochow et al reviewed the clinical course of 120 myeloma patients receiving 60 mg/kg of CPA and failed to find any difference in hematologic toxicity between patients with normal and abnormal renal function. 5 Therefore, dose adjustment of CPA in the presence of renal insufficiency was not recommended. 5, 6 The dose of CPA in the present patient was 2 g/m 2 /day (57 mg/kg/day) for 2 days, at which level severe cardiotoxicity is not common. We considered that the dose was safe even if the toxicity was equivalent to that seen after a 2-fold higher dose in patients with normal renal function, because 7 g/m 2 of CPA has been administered safely in myeloma patients without excessive toxicities. 17 However, this patient developed severe myopericarditis manifesting as left ventricular failure. In addition, recovery from myelosuppression was prolonged compared with that seen in patients with normal renal function (approximately 3 weeks vs 2 weeks after CPA at the described dose). As shown in Figure  1 , the serum concentration of CPA metabolites remained high and did not decline in the first 24 h after CPA infusion. Although large inter-individual differences in the elimination of alkylating metabolites is recognized, the serum level of CPA metabolites begins to decrease in the first 24 h even in patients with renal impairment. 3 In previous studies in patients with renal failure, the dose of CPA was relatively low (7 mg/kg to 60 mg/kg) and renal failure was mild (15-34 ml/min of creatinine clearance). 3, 5 Therefore, the high doses of CPA and/or the severe renal failure (serum creatinine 4.2 mg/dl, creatinine clearance 11.2 ml/min) in the present patient might have altered the break-down of CPA and resulted in the development of severe toxicities. In such a situation, it may be prudent to decrease the dose of cyclophosphamide or to substitute it for another agent. To what degree we should decrease the dose of CPA could not be determined, but the chemotherapy-related toxicity in the present patient was greater than that seen in myeloma Bone Marrow Transplantation patients without renal insufficiency who receive 6 or 7 g/m 2 of CPA. 17, 18 There have been no data on the levels of alkylating activity in patients receiving 6-7 g/m 2 of CPA. However, we believe that the levels in this patient were far higher than would be expected in patients receiving 6 or 7 g/m 2 of CPA, because the levels of both CPA and its metabolites rapidly decline in patients with normal renal function. Therefore, we recommend that the dose of CPA for myeloma patients with severe renal failure undergoing PBSC mobilization should be half of the standard dose, at maximum.
